Repligen to Present at Jefferies 2018 Global Healthcare Conference
23 May 2018 - 9:30PM
Repligen Corporation (NASDAQ:RGEN), a global bioprocessing company
focused on the development and commercialization of highly
innovative technologies to improve biopharmaceutical manufacturing
processes, today announced that Jon K. Snodgres, Chief Financial
Officer, will present at the Jefferies 2018 Global Healthcare
Conference. The conference will take place on June 5-8 in New York
City, and the Repligen presentation is scheduled for Wednesday,
June 6 at 3:00 p.m. EDT.
A live webcast of the presentation will be
accessible through the Investor Relations section of Repligen’s
website, and will be archived for a period of time following the
live event. About Repligen CorporationRepligen
Corporation (NASDAQ:RGEN) is a global bioprocessing company that
develops and commercializes highly innovative products that deliver
cost and process efficiencies to biological drug manufacturers
worldwide. Our portfolio includes Protein products (Protein A
affinity ligands, cell culture growth factors), Chromatography
products (OPUS® pre-packed columns, chromatography resins, ELISA
kits) and Filtration products (including XCell™ ATF systems,
TangenX™ Sius™ flat sheet TFF cassettes, and Spectrum KrosFlo™
hollow fiber TFF cartridges and systems). The Protein A ligands and
growth factors that we produce are key components of Protein A
affinity resins and cell culture media, respectively. Protein A
affinity resins are the industry standard for downstream separation
and purification of monoclonal antibody-based therapeutics. Growth
factors are used in upstream processes to accelerate cell growth
and productivity. Our innovative line of OPUS® chromatography
columns, used in downstream processes for bench- through
commercial-scale purification needs, are delivered pre-packed to
our customers with their choice of resin and to their bed height
preferences. Our XCell™ ATF Systems, available in stainless steel
and single-use configurations, continuously eliminate waste from a
bioreactor to concentrate cells and significantly increase
productivity in upstream processes. Single-use SIUS™ TFF cassettes
and hardware are used for biologic drug concentration in downstream
filtration processes, and Spectrum KrosFlo™ TFF cartridges and
systems are used in both upstream and downstream filtration
processes. Repligen’s corporate headquarters are in Waltham, MA
(USA), with additional administrative and manufacturing operations
in Shrewsbury, MA, Rancho Dominguez, CA, Lund, Sweden and
Ravensburg, Germany.
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including risks discussed from time to time
in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.
Source: Repligen Corporation Sondra Newman Senior Director
Investor Relations(781) 419-1881 snewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From May 2023 to May 2024